Inactive Instrument

Highlights ContraVir Pharmaceuticals Inc OTC Bulletin Board

Equities

US21234W1036

End-of-day quote OTC Bulletin Board Other stock markets
- ^USD	-

21/05	Hepion Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
22/04	Sector Update: Health Care Stocks Increase Late Afternoon	MT

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Hepion Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	22/05	CI
North American Morning Briefing: Stock Futures Rise, Busy Week of Earnings Ahead	22/04	DJ
Hepion Pharmaceuticals, Inc. Initiates Wind-Down Activities in Phase 2b ?ASCEND-NASH? Trial	20/04	CI
Hepion Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	17/04	CI
North American Morning Briefing : Futures Pause -2-	08/12	DJ
Hepion Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	21/11	CI
Hepion Pharmaceuticals Announces Major Reductions in Liver Stiffness with Rencofilstat Treatment in 17-Week Phase 2 Study of Advanced (F3) Mash Liver Disease	14/11	CI
Hepion Pharmaceuticals, Inc. Announces the Publication of New Research Study in Mice	25/23/25	CI
Hepion Pharmaceuticals, Inc. Announces Results from A Study with in Which the Anti-Cancer Activity of Hepion's Lead Drug Candidate, Rencofilstat	21/23/21	CI
Hepion Pharmaceuticals, Inc. Announces Positive Results from Translational Research Study	14/23/14	CI
Hepion Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	15/23/15	CI
Hepion Pharmaceuticals Announces Passing of Key Safety Milestone in Phase 2b ‘ASCEND-NASH’ Trial of Rencofilstat	15/23/15	CI
Hepion's NASH drug meets main goal in mid-stage trial	22/23/22	RE
Hepion Pharmaceuticals, Inc. Announces Positive Topline Results from Its Recently Completed Phase 2 Altitude-Nash Clinical Trial	22/23/22	CI
Hepion Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	13/23/13	CI
Hepion Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	11/23/11	CI
Hepion Pharmaceuticals Secures European Patent for Liver Disease Drug Candidate Rencofilstat	02/23/02	MT
Hepion Pharmaceuticals, Inc. Announces Positive Results of Preclinical Studies Examining Rencofilstat as A Potential Therapeutic for Multiple Myeloma	18/23/18	CI
Hepion Pharmaceuticals, Inc. Presents of Preclinical Study Highlighting Anti-Cancer Activity of Rencofilstat in Combination with Proteosome Inhibitors	11/23/11	CI
Hepion Pharmaceuticals Announces Early Completion of Enrollment in Phase 2 'Altitude-Nash' Liver Function Trial	05/22/05	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights ContraVir Pharmaceuticals Inc OTC Bulletin Board

Equities

US21234W1036

Highlights

Filters